Insight Molecular Diagnostics (IMDX) Other Non-Current Liabilities (2019 - 2026)

Insight Molecular Diagnostics (IMDX) has 8 years of Other Non-Current Liabilities data on file, last reported at $37.8 million in Q1 2026.

• Quarterly Other Non-Current Liabilities rose 1340.78% year-over-year to $37.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $37.8 million (up 1340.78% YoY) and the FY2025 annual result came in at $43.5 million, up 22.94% from the prior year.
• Other Non-Current Liabilities slipped to $37.8 million in Q1 2026 per IMDX's latest filing, from $43.5 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $57.2 million in Q2 2022, with the low at $2.0 million in Q2 2024.
• Average Other Non-Current Liabilities over 5 years is $28.3 million, with a median of $37.8 million recorded in 2026.
• Year-over-year, Other Non-Current Liabilities sank 95.6% in 2023 and soared 2022.9% in 2025.
• Insight Molecular Diagnostics' Other Non-Current Liabilities stood at $42.6 million in 2022, then fell by 5.71% to $40.2 million in 2023, then declined by 12.02% to $35.3 million in 2024, then gained by 22.94% to $43.5 million in 2025, then declined by 13.0% to $37.8 million in 2026.
• Business Quant data shows IMDX's Other Non-Current Liabilities at $37.8 million in Q1 2026, $43.5 million in Q4 2025, and $43.9 million in Q3 2025.